Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

What Was Tested

This randomized controlled trial paper looks at Tirzepatide.

In this study, the researchers used continuous glucose monitoring (CGM) to compare the 24 h glucose profile for participants given tirzepatide compared with those given insulin degludec.

Why It Was Studied

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist under development for the treatment of type 2 diabetes.

Who Took Part

PubMed indexes the participants as adults.

Participants were stratified by country, HbA1c concentration, and concomitant oral antihyperglycaemic medication.

A subset of these patients with a normal wake-sleep cycle were enrolled into this substudy, and interstitial glucose values were collected by CGM for approximately 7 days at baseline, 24 weeks, and 52 weeks.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.

The Tirzepatide group and the comparison group ran side by side rather than switching.

This substudy of the open-label, parallel-group, phase 3 SURPASS-3 trial, was done at 45 sites across six countries (Hungary, Poland, Romania, Spain, Ukraine, and the USA).

This was a substudy of the trial registered with ClinicalTrials.gov, NCT03882970, and is complete.

What Was Measured

The subject headings attached to it are Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Glycemic Control and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Tirzepatide.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Tirzepatide compound page, all human trials.